Why is Orbimed Backing Out of Amarin?

Orbimed Advisors, managed by Samuel Isaly, is a hedge fund with a focus on the healthcare sector. At the end of June, according to Orbimed’s 13F filing, the fund owned 1.2 million shares of Irish drug manufacturer Amarin Corporation plc (NASDAQ:AMRN). This is significantly smaller than the 1.8 million shares the fund opened the year with. The sales have continued during the third quarter: Orbimed recently filed with the SEC to disclose that it had sold over 230,000 shares on September 4th at an average price of $14.43. The stock has doubled this year partly due to FDA approval of Amarin’s Vascepa drug, designed to treat high cholesterol. We could easily see Orbimed selling some shares to lock in profits that it has earned from Amarin’s rise this year, yet the fact that the fund has disposed of such a large portion of the stake that it began the year with suggests that it does in fact believe that the stock is now overvalued.

Amarin Corporation plc (ADR) (NASDAQ:AMRN)

We looked at Amarin in depth last month. Amarin’s business prospects depend on the successful production and marketing of Vascepa to compete with rival cholesterol drugs such as GlaxoSmithKline plc (NYSE:GSK)’s Lovaza. If Vascepa can be seen as a credible alternative, the company could bring in hundreds of millions of dollars in annual revenue (at least before giving a cut of sales to any marketing partners). Sell-side analyst projections average out to five cents of earnings per share in 2013, though there is a wide range of estimates. The company will also have a few years of patent exclusivity to help justify the current market capitalization of $2.2 billion.

It will be interesting to see if other hedge funds report smaller stakes in Amarin in their filings for the third quarter when those are released in November. We know that Bain Capital’s Brookside Capital initiated a position of 4.9 million shares during the second quarter (find more stock picks from Brookside Capital). Orbimed was not alone in selling out of the stock between April and June, however: Ardsley Partners, managed by Philip Hempleman, sold more than half the shares it had started the quarter with (see more buying and selling activity at Ardsley Partners).

We’ve already mentioned GlaxoSmithKline as a potential competitor. The pharmaceutical giant trades at 14 times trailing earnings and 10 times forward earnings estimates, and also pays a dividend yield of 4.7%. It certainly does not have as much potential as Amarin, but could be a good value stock. Merck & Co., Inc. (NYSE:MRK) is another large-cap pharmaceutical company. Its 4.5% dividend yield is in the same range as GlaxoSmithKline’s, but it is priced higher relative to its earnings with trailing and forward P/E multiples of 20 and 12, respectively. We would prefer either of these stocks on a value basis, but investors looking for a speculative but potentially high-reward healthcare opportunity might prefer to compare Amarin to weight loss treatment providers VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). The two drug developers are set for a nasty battle in doctor’s offices throughout the U.S. and the world as both appear to be effective in causing weight loss and are FDA approved- but also have safety concerns. Both of these companies have market capitalizations of about $2 billion. We think that the market opportunity for weight loss drugs- particularly if they can break into the vanity market- is greater than that for high cholesterol. If we weren’t worried about potential side effects, we would easily recommend either Vivus, Arena, or both over Amarin given this opportunity and the fact that all three companies have similar market capitalizations.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!